Since we previously demonstrated that GPR56 expression plays an essential role in the survival of AML cells via inhibition of apoptosis15, in the present study we developed a novel drug that inhibits EVI1-dependent GPR56 expression. Here, RUNX1 is linked to acute myeloid leukemia.